Skip to main content
. 2020 Aug 18;22(9):e13963. doi: 10.1111/jch.13963

Table 6.

Biochemistry test results at 6‐ and 12‐mo post‐procedure follow‐up

Characteristics RDN group (n = 28) Control group (n = 28) P
PRA (ng/mL)/h
Baseline 0.20 (0.20 ~ 0.55) 0.20 (0.20 ~ 0.30) .150
6 mo 1.40 (1.20 ~ 2.20) 1.40 (1.20 ~ 1.89) .625
12 mo 1.64 (1.14 ~ 2.40) 1.40 (1.15 ~ 1.67) .097
PAC (pg/mL)
Baseline 434.5 (227.9 ~ 680.3) 310.0 (176.0 ~ 538.0) .150
6 mo 93.3 (74.0 ~ 140.4) 143.0 (103.0 ~ 188.0) .010
12 mo 95.0 (70.0 ~ 128.2) 141.0 (94.3 ~ 187.0) .053
ARR
Baseline 185.8 (62.3 ~ 329.4) 103.00 (54.2 ~ 257.5) .372
6 mo 6.8 (4.7 ~ 10.7) 9.9 (5.8 ~ 15.5) .074
12 mo 8.4 (6.5 ~ 10.0) 7.9 (5.7 ~ 13.5) .501
Serum potassium (mmol/L)
Baseline 3.44 ± 0.71 3.43 ± 0.70 .939
6 mo 4.19 ± 0.20 4.14 ± 0.29 .453
12 mo 4.22 ± 0.27 4.11 ± 0.44 .310
eGFR (mL/(min/1.73 m2))
Baseline 88.2 ± 11.4 84.3 ± 14.9 .939
6 mo 89.8 ± 9.0+ 86.7 ± 10.6+ .771
12 mo 82.3 ± 10.2+ 84.8 ± 9.5+ .692

Data are presented as mean ± SD, or median (IQR). +: compared with baseline level in the same group, P > .05.

Abbreviations: ARR, aldosterone‐to‐renin ratio; eGFR, estimated glomerular filtration rate, calculated using the Cockcroft‐Gault formula; PAC, plasma aldosterone concentration; PRA, plasma renin activity.